Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00264017
Status:
COMPLETED
Last Update Posted:
2005-12-12
First Post:
2005-12-06
Brief Title:
Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis
Sponsor:
Dattoli Cancer Center and Brachytherapy Research Institute
Organization:
Dattoli Cancer Center and Brachytherapy Research Institute
Study Overview
Official Title:
Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax-A 3 Month Retrospective Efficacy Analysis
Status:
COMPLETED
Status Verified Date:
2005-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In the past ten years newer drugs with more selective affinity for the alpha-receptor have been introduced Alfuzosin Uroxatral and TamulosinFlomax are two second generation alpha-blockers In the course of our clinical proctice both drugs have been used routinely This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None